TWI825524B - 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 - Google Patents
用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 Download PDFInfo
- Publication number
- TWI825524B TWI825524B TW110146540A TW110146540A TWI825524B TW I825524 B TWI825524 B TW I825524B TW 110146540 A TW110146540 A TW 110146540A TW 110146540 A TW110146540 A TW 110146540A TW I825524 B TWI825524 B TW I825524B
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- sub
- reaction
- alkyl
- isopropyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 54
- 230000002194 synthesizing effect Effects 0.000 title claims abstract description 14
- FWCVZAQENIZVMY-UHFFFAOYSA-N 2-hydroxy-6-[[2-(2-propan-2-ylpyrazol-3-yl)pyridin-3-yl]methoxy]benzaldehyde Chemical compound CC(C)N1N=CC=C1C1=NC=CC=C1COC1=CC=CC(O)=C1C=O FWCVZAQENIZVMY-UHFFFAOYSA-N 0.000 title abstract description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 118
- 125000000217 alkyl group Chemical group 0.000 claims description 42
- 238000006243 chemical reaction Methods 0.000 claims description 37
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 27
- -1 boric acid compound Chemical class 0.000 claims description 18
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 17
- 239000000126 substance Substances 0.000 claims description 7
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 claims description 4
- 238000005804 alkylation reaction Methods 0.000 claims description 3
- 239000004327 boric acid Substances 0.000 claims description 2
- 239000000543 intermediate Substances 0.000 abstract description 9
- 102000001554 Hemoglobins Human genes 0.000 abstract description 3
- 108010054147 Hemoglobins Proteins 0.000 abstract description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 239000001301 oxygen Substances 0.000 abstract description 3
- 229910052760 oxygen Inorganic materials 0.000 abstract description 3
- 208000007056 sickle cell anemia Diseases 0.000 abstract description 3
- 238000000634 powder X-ray diffraction Methods 0.000 description 25
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 20
- 239000011541 reaction mixture Substances 0.000 description 19
- 230000015572 biosynthetic process Effects 0.000 description 18
- 238000003786 synthesis reaction Methods 0.000 description 18
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical group [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 14
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
- 239000002253 acid Substances 0.000 description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 11
- 239000001257 hydrogen Substances 0.000 description 11
- 229910052739 hydrogen Inorganic materials 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 230000005855 radiation Effects 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 238000010511 deprotection reaction Methods 0.000 description 9
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
- 125000004187 tetrahydropyran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 239000002002 slurry Substances 0.000 description 7
- DGXAGETVRDOQFP-UHFFFAOYSA-N 2,6-dihydroxybenzaldehyde Chemical compound OC1=CC=CC(O)=C1C=O DGXAGETVRDOQFP-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 229910052801 chlorine Inorganic materials 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 6
- 230000008025 crystallization Effects 0.000 description 6
- 238000006116 polymerization reaction Methods 0.000 description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- CZNAXKQIUMAWPD-UHFFFAOYSA-N 3-(chloromethyl)-2-(2-propan-2-ylpyrazol-3-yl)pyridine dihydrochloride Chemical compound Cl.Cl.CC(C)n1nccc1-c1ncccc1CCl CZNAXKQIUMAWPD-UHFFFAOYSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- FJKIXWOMBXYWOQ-UHFFFAOYSA-N ethenoxyethane Chemical compound CCOC=C FJKIXWOMBXYWOQ-UHFFFAOYSA-N 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical group [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- AWBFONKUPONBFE-UHFFFAOYSA-N 2,6-bis(1-ethoxyethoxy)benzaldehyde Chemical compound C(C)OC(C)OC1=C(C=O)C(=CC=C1)OC(C)OCC AWBFONKUPONBFE-UHFFFAOYSA-N 0.000 description 3
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical class C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000006170 formylation reaction Methods 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 239000011261 inert gas Substances 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 235000009518 sodium iodide Nutrition 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 2
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 2
- 229910002483 Cu Ka Inorganic materials 0.000 description 2
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical group C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- QPFYXYFORQJZEC-FOCLMDBBSA-N Phenazopyridine Chemical compound NC1=NC(N)=CC=C1\N=N\C1=CC=CC=C1 QPFYXYFORQJZEC-FOCLMDBBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 230000022244 formylation Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- LCEDQNDDFOCWGG-UHFFFAOYSA-N morpholine-4-carbaldehyde Chemical compound O=CN1CCOCC1 LCEDQNDDFOCWGG-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 2
- 229940070891 pyridium Drugs 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- HMPDWSBKPCOQDW-UHFFFAOYSA-N (2-chloropyridin-3-yl)methanol Chemical compound OCC1=CC=CN=C1Cl HMPDWSBKPCOQDW-UHFFFAOYSA-N 0.000 description 1
- BZODCTOZQNOXGG-UHFFFAOYSA-N 3-[[2-(2-propan-2-ylpyrazol-3-yl)pyridin-3-yl]methoxy]phenol Chemical compound OC1=CC(=CC=C1)OCC=1C(=NC=CC1)C1=CC=NN1C(C)C BZODCTOZQNOXGG-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FXKDDCBFUOGTQM-UHFFFAOYSA-N [2-(2-propan-2-ylpyrazol-3-yl)pyridin-3-yl]methanol Chemical compound CC(C)N1N=CC=C1C1=NC=CC=C1CO FXKDDCBFUOGTQM-UHFFFAOYSA-N 0.000 description 1
- HMHZTYYTZHCTOW-UHFFFAOYSA-N [2-(2-propan-2-ylpyrazol-3-yl)pyridin-3-yl]methanol hydrochloride Chemical compound Cl.CC(C)n1nccc1-c1ncccc1CO HMHZTYYTZHCTOW-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- USVZFSNDGFNNJT-UHFFFAOYSA-N cyclopenta-1,4-dien-1-yl(diphenyl)phosphane (2,3-dichlorocyclopenta-1,4-dien-1-yl)-diphenylphosphane iron(2+) Chemical group [Fe++].c1cc[c-](c1)P(c1ccccc1)c1ccccc1.Clc1c(cc[c-]1Cl)P(c1ccccc1)c1ccccc1 USVZFSNDGFNNJT-UHFFFAOYSA-N 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- WBGPNPZUWVTYAA-UHFFFAOYSA-N methane;dihydrochloride Chemical class C.Cl.Cl WBGPNPZUWVTYAA-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
- C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
- C07C47/56—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/65—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by splitting-off hydrogen atoms or functional groups; by hydrogenolysis of functional groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
- C07C47/56—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups
- C07C47/565—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups all hydroxy groups bound to the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662335583P | 2016-05-12 | 2016-05-12 | |
| US62/335,583 | 2016-05-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202237575A TW202237575A (zh) | 2022-10-01 |
| TWI825524B true TWI825524B (zh) | 2023-12-11 |
Family
ID=60268009
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110146540A TWI825524B (zh) | 2016-05-12 | 2017-05-10 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
| TW108110285A TWI752307B (zh) | 2016-05-12 | 2017-05-10 | 新穎化合物及製造化合物之方法 |
| TW106115528A TWI663160B (zh) | 2016-05-12 | 2017-05-10 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW108110285A TWI752307B (zh) | 2016-05-12 | 2017-05-10 | 新穎化合物及製造化合物之方法 |
| TW106115528A TWI663160B (zh) | 2016-05-12 | 2017-05-10 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US10077249B2 (enExample) |
| EP (2) | EP3909941A1 (enExample) |
| JP (2) | JP7398193B2 (enExample) |
| KR (3) | KR20220139437A (enExample) |
| CN (2) | CN115819400A (enExample) |
| AR (1) | AR108435A1 (enExample) |
| AU (2) | AU2017261730B2 (enExample) |
| DK (1) | DK3454854T3 (enExample) |
| EA (2) | EA037014B1 (enExample) |
| ES (1) | ES2881426T3 (enExample) |
| HR (1) | HRP20211193T1 (enExample) |
| HU (1) | HUE055045T2 (enExample) |
| IL (3) | IL284406B2 (enExample) |
| MX (3) | MX387149B (enExample) |
| PL (1) | PL3454854T3 (enExample) |
| PT (1) | PT3454854T (enExample) |
| SG (2) | SG11201809344QA (enExample) |
| TW (3) | TWI825524B (enExample) |
| WO (1) | WO2017197083A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2790358T3 (es) | 2011-12-28 | 2020-10-27 | Global Blood Therapeutics Inc | Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular |
| CA3142817A1 (en) | 2011-12-28 | 2013-07-04 | Global Blood Therapeutics, Inc. | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| EP3919056B1 (en) | 2013-03-15 | 2024-08-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| EP2968299B1 (en) | 2013-03-15 | 2021-01-20 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| CN112500338A (zh) | 2013-03-15 | 2021-03-16 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
| EA202092627A1 (ru) | 2013-11-18 | 2021-09-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| SG10201911662YA (en) | 2014-02-07 | 2020-02-27 | Global Blood Therapeutics Inc | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| MA41841A (fr) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs |
| HUE072191T2 (hu) | 2015-12-04 | 2025-10-28 | Global Blood Therapeutics Inc | A 2-hidoxi-6-((2-(1-izopropil-1H-pirazol-5-il)piridin-3-il)metoxi)benzaldehid adagolási rendje |
| TWI825524B (zh) | 2016-05-12 | 2023-12-11 | 美商全球血液治療公司 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
| TWI778983B (zh) | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
| PT3448859T (pt) | 2017-03-20 | 2019-10-25 | Forma Therapeutics Inc | Composições de pirrolopirrole como ativadores de piruvato quinase (pkr). |
| US12053458B2 (en) | 2018-09-19 | 2024-08-06 | Novo Nordisk Health Care Ag | Treating sickle cell disease with a pyruvate kinase R activating compound |
| ES2989438T3 (es) | 2018-09-19 | 2024-11-26 | Novo Nordisk Healthcare Ag | Activación de la piruvato cinasa R |
| US11014884B2 (en) | 2018-10-01 | 2021-05-25 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin |
| CR20210335A (es) | 2018-11-19 | 2021-09-14 | Global Blood Therapeutics Inc | Compuestos de 2-formil-3-hidroxifeniloximetilo capaces de modular la hemoglobina |
| US12492180B2 (en) | 2018-12-21 | 2025-12-09 | Curia Spain, S.A.U. | Process and intermediates for the preparation of Voxelotor |
| WO2020127945A1 (en) * | 2018-12-21 | 2020-06-25 | Bionice, S.L.U. | Process and intermediates for the synthesis of voxelotor |
| EP3693364A1 (en) * | 2019-02-11 | 2020-08-12 | Sandoz Ag | Crystalline salts of a hemoglobin s allosteric modulator |
| KR102727505B1 (ko) * | 2019-09-12 | 2024-11-06 | 아심켐 래보러토리즈 (푸신) 컴퍼니, 리미티드 | 2,6-디히드록시벤즈알데히드의 연속 제조 장치 및 그 응용 |
| CN114615977B (zh) | 2019-09-19 | 2025-01-14 | 诺沃挪第克健康护理股份公司 | 丙酮酸激酶r(pkr)活化组合物 |
| US20230015823A1 (en) | 2019-11-19 | 2023-01-19 | Global Blood Therapeutics, Inc. | Methods of administering voxelotor |
| GB202002560D0 (en) * | 2020-02-24 | 2020-04-08 | Johnson Matthey Plc | Crystalline forms of voxelotor, and processes for the preparation thereof |
| IT202000009970A1 (it) * | 2020-05-05 | 2021-11-05 | Dipharma Francis Srl | Procedimento per la preparazione di un farmaco per il trattamento dell’anemia falciforme |
| IT202000025135A1 (it) * | 2020-10-23 | 2022-04-23 | Dipharma Francis Srl | Procedimento per la preparazione di un farmaco per il trattamento dell’anemia falciforme |
| WO2021224280A1 (en) * | 2020-05-05 | 2021-11-11 | Dipharma Francis S.R.L. | Synthesis of a sickle cell disease agent and intermediates thereof |
| CN112047924B (zh) * | 2020-10-10 | 2023-04-18 | 山东汇海医药化工有限公司 | 一种沃克洛多的制备方法 |
| CN116710441A (zh) * | 2020-11-06 | 2023-09-05 | 全球血液疗法公司 | 制备2-羟基-6-((2-(1-异丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)苯甲醛的方法 |
| TW202233589A (zh) * | 2020-11-06 | 2022-09-01 | 美商全球血液治療公司 | 2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)苯甲醛之製備方法 |
| US11611474B2 (en) | 2020-12-28 | 2023-03-21 | Juniper Networks, Inc. | Edge controller with network performance parameter support |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| AU2022381755A1 (en) | 2021-11-05 | 2024-05-16 | Global Blood Therapeutics, Inc. | Methods of treating sickle cell disease with voxelotor |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104135859A (zh) * | 2011-12-28 | 2014-11-05 | 全球血液疗法公司 | 取代的苯甲醛化合物及其用于增加组织氧合的方法 |
| TW201612171A (en) * | 2014-02-07 | 2016-04-01 | Global Blood Therapeutics Inc | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
Family Cites Families (254)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL218146A (enExample) | 1956-02-13 | 1900-01-01 | ||
| BE787576A (fr) | 1971-08-13 | 1973-02-14 | Hoechst Ag | Derives de benzofuranne et leur utilisation comme azureurs optiques |
| BE787580A (fr) | 1971-08-13 | 1973-02-14 | Hoechst Ag | Procede de preparation de derives du furanne |
| GB1409865A (en) | 1973-02-13 | 1975-10-15 | Science Union & Cie | Dihydropyridines derivatives their preparation and pharmaceu tical compositions containing them |
| GB1593417A (en) | 1976-12-22 | 1981-07-15 | Squibb & Sons Inc | Carbocyclic-fused pyrazolopyridine derivatives |
| US4062858A (en) | 1976-12-22 | 1977-12-13 | E. R. Squibb & Sons, Inc. | Derivatives of 5,6-dihydrobenzo[5,6]cyclohepta[1,2-b]pyrazolo[4,3-e]pyridin-11(1H)-ones and 11(1H)-imines |
| DE2964427D1 (en) | 1978-10-04 | 1983-02-03 | Ciba Geigy Ag | Process for the preparation of furanyl-benzazoles |
| DE2853765A1 (de) | 1978-12-13 | 1980-06-26 | Bayer Ag | Verfahren zur herstellung von benzimidazolylbenzofuranen |
| DE2904829A1 (de) | 1979-02-08 | 1980-08-14 | Bayer Ag | Verfahren zur herstellung von benzimidazolylbenzofuran |
| HU190774B (en) | 1979-06-29 | 1986-11-28 | The Wellcome Foundation Ltd,Gb | Process for preparing ether derivatives with pharmacological activity |
| GB2090830B (en) | 1980-12-18 | 1984-09-26 | Wellcome Found | Formyl ether derivatives |
| JPS5929667A (ja) | 1982-08-13 | 1984-02-16 | Otsuka Pharmaceut Co Ltd | カルボスチリル誘導体および強心剤 |
| US4478834A (en) | 1983-02-11 | 1984-10-23 | Usv Pharmaceutical Corporation | Dihydropyridines and their use in the treatment of asthma |
| GB8402740D0 (en) | 1984-02-02 | 1984-03-07 | Scras | Furo-(3 4-c)-pyridine derivatives |
| JPS6140236A (ja) | 1984-08-02 | 1986-02-26 | Yamanouchi Pharmaceut Co Ltd | ハイドロキノン誘導体 |
| DE3431004A1 (de) | 1984-08-23 | 1986-03-06 | Hoechst Ag, 6230 Frankfurt | Neue 3-pyridylverbindungen und verfahren zu ihrer herstellung |
| DD226590A1 (de) | 1984-09-07 | 1985-08-28 | Univ Leipzig | Mittel zur phagenhemmung in mikrobiellen produktionsprozessen |
| GB8603475D0 (en) | 1986-02-12 | 1986-03-19 | Glaxo Group Ltd | Chemical compounds |
| DK111387A (da) | 1986-03-05 | 1987-09-06 | Otsuka Pharma Co Ltd | Carbostyrilderivater og salte deraf, laegemiddel indeholdende saadanne derivater samt fremgangsmaade til fremstilling af derivaterne |
| US4831041A (en) | 1986-11-26 | 1989-05-16 | Fujisawa Pharmaceutical Co., Ltd. | Imidazopyridine compounds and processes for preparation thereof |
| EP0278686A1 (en) | 1987-02-07 | 1988-08-17 | The Wellcome Foundation Limited | Pyridopyrimidines methods for their preparation and pharmaceutical formulations thereof |
| DD258226A1 (de) | 1987-03-05 | 1988-07-13 | Fahlberg List Veb | Verfahren zur herstellung von aroxymethylchinoxalinen |
| JPH07121937B2 (ja) | 1987-03-18 | 1995-12-25 | 大塚製薬株式会社 | カルボスチリル誘導体 |
| JPS63258463A (ja) | 1987-04-14 | 1988-10-25 | Kumiai Chem Ind Co Ltd | ２−フエノキシピリミジン誘導体及び除草剤 |
| GB8711802D0 (en) | 1987-05-19 | 1987-06-24 | Fujisawa Pharmaceutical Co | Dithioacetal compounds |
| GB8718940D0 (en) | 1987-08-11 | 1987-09-16 | Glaxo Group Ltd | Chemical compounds |
| US4920131A (en) | 1987-11-03 | 1990-04-24 | Rorer Pharmaceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene D4 |
| JP2650038B2 (ja) | 1988-01-27 | 1997-09-03 | サントリー株式会社 | ピロリチジン化合物およびその用途 |
| EP0336369A1 (en) | 1988-04-04 | 1989-10-11 | E.R. Squibb & Sons, Inc. | 3-Acylamino-1-[[[(substituted sulfonyl)amino]carbonyl]amino]2-azetidinones |
| US4952574A (en) | 1988-09-26 | 1990-08-28 | Riker Laboratories, Inc. | Antiarrhythmic substituted N-(2-piperidylmethyl)benzamides |
| IE81170B1 (en) | 1988-10-21 | 2000-05-31 | Zeneca Ltd | Pyridine derivatives |
| DD276479A1 (de) | 1988-10-26 | 1990-02-28 | Fahlberg List Veb | Verfahren zur herstellung von benzo/b/fur-2-ylchinoxalinen |
| DD276480A1 (de) | 1988-10-26 | 1990-02-28 | Fahlberg List Veb | Verfahren zur herstellung von naphtho/2,1-b/fur-2-ylchinoxalinen |
| US5236917A (en) | 1989-05-04 | 1993-08-17 | Sterling Winthrop Inc. | Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof |
| IT1230859B (it) | 1989-06-05 | 1991-11-08 | Corvi Camillo Spa | 2 alchinilfenoli sostituiti ad azione anti infiammatoria, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono. |
| EP0453210A3 (en) | 1990-04-19 | 1993-01-13 | Imperial Chemical Industries Plc | Pyridine derivatives |
| AU641769B2 (en) | 1990-06-18 | 1993-09-30 | Merck & Co., Inc. | Inhibitors of HIV reverse transcriptase |
| CN1034934C (zh) | 1990-06-19 | 1997-05-21 | 明治制果株式会社 | 血管紧张素ii拮抗性吡啶衍生物的制备方法 |
| NL9001752A (nl) | 1990-08-02 | 1992-03-02 | Cedona Pharm Bv | Nieuwe 1,4-dihydropyridinederivaten. |
| IL99731A0 (en) | 1990-10-18 | 1992-08-18 | Merck & Co Inc | Hydroxylated pyridine derivatives,their preparation and pharmaceutical compositions containing them |
| US5403816A (en) | 1990-10-25 | 1995-04-04 | Kumiai Chemical Industry Co., Ltd. | Picolinic acid derivative and herbicidal composition |
| JPH05301872A (ja) | 1992-04-23 | 1993-11-16 | Kumiai Chem Ind Co Ltd | ピコリン酸誘導体及び除草剤 |
| AU1183992A (en) | 1991-02-08 | 1992-09-07 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Complexing agents |
| JPH0641118A (ja) | 1991-05-31 | 1994-02-15 | Kumiai Chem Ind Co Ltd | ピコリン酸誘導体及び除草剤 |
| US5185251A (en) | 1991-06-07 | 1993-02-09 | Merck & Co., Inc. | Microbial transformation of a substituted pyridinone using actinoplanacete sp. MA 6559 |
| JP2600644B2 (ja) | 1991-08-16 | 1997-04-16 | 藤沢薬品工業株式会社 | チアゾリルベンゾフラン誘導体 |
| FR2680512B1 (fr) | 1991-08-20 | 1995-01-20 | Adir | Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| US5202243A (en) | 1991-10-04 | 1993-04-13 | Merck & Co., Inc. | Method of hydroxylating 3-[2-(benzoxazol-2-yl)ethyl]-5-ethyl-6-methyl-2-(1H)-pyridinone by incubation with liver slices |
| GB9203798D0 (en) | 1992-02-21 | 1992-04-08 | Fujisawa Pharmaceutical Co | Quinolylbenzofuran derivatives,processes for preparation thereof and pharmaceutical composition comprising the same |
| WO1994001406A1 (de) | 1992-07-01 | 1994-01-20 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Kontrastmittel für die mr diagnostik |
| US5290941A (en) | 1992-10-14 | 1994-03-01 | Merck & Co., Inc. | Facile condensation of methylbenzoxazoles with aromatic aldehydes |
| HU224548B1 (hu) | 1993-04-07 | 2005-10-28 | Taiho Pharmaceutical Co. Ltd. | Tiazolidinszármazékok és ezeket tartalmazó gyógyszerkészítmények, valamint eljárás előállításukra |
| DE4318550A1 (de) | 1993-06-04 | 1994-12-08 | Boehringer Mannheim Gmbh | Aryliden-4-oxo-2-thioxo-3- thiazolidincarbonsäuren, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| AU672699B2 (en) | 1993-06-30 | 1996-10-10 | Sankyo Company Limited | Amide and urea derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses |
| JPH0725882A (ja) | 1993-07-07 | 1995-01-27 | Res Dev Corp Of Japan | アクロメリン酸ｂおよびｅを製造するための中間体と、その製造方法 |
| DE69418789T2 (de) | 1993-08-05 | 1999-12-02 | Hoechst Marion Roussel, Inc. | 2-(Piperidin-4-yl, Pyridin-4-yl und Tetrahydropyridin-4-yl)-benzofuran-7-carbamat Derivate, ihre Herstellung und Verwendung als Acetylcholinesterase Inhibitoren |
| EP0640609A1 (en) | 1993-08-24 | 1995-03-01 | Ono Pharmaceutical Co., Ltd. | Fused phenol derivatives having inhibitory activity on TXA2 synthetase, and 5-lipoxygenase and scavenging activity on oxygen species |
| US5965566A (en) | 1993-10-20 | 1999-10-12 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| US5880131A (en) | 1993-10-20 | 1999-03-09 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| US5840900A (en) | 1993-10-20 | 1998-11-24 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| US5605976A (en) | 1995-05-15 | 1997-02-25 | Enzon, Inc. | Method of preparing polyalkylene oxide carboxylic acids |
| WO1995014015A1 (en) | 1993-11-19 | 1995-05-26 | Ciba-Geigy Ag | Benzothiophene derivatives possessing a methoxyimino substituent as microbicides |
| EP0658559A1 (de) | 1993-12-14 | 1995-06-21 | Chemisch Pharmazeutische Forschungsgesellschaft m.b.H. | Thienothiazinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als 5-dipoxygenase und Cyclooxygenaseinhibitoren |
| HUT74385A (en) | 1994-02-14 | 1996-12-30 | Merrell Pharma Inc | Novel mercaptoacetylamido 1,3,4,5-tetrahydro-benzo[c]azepin-3-one disulfide derivatives useful as inhibitors of enkephalinase and ace |
| GB9420557D0 (en) | 1994-10-12 | 1994-11-30 | Zeneca Ltd | Aromatic compounds |
| DE4442050A1 (de) | 1994-11-25 | 1996-05-30 | Hoechst Ag | Heterospiroverbindungen und ihre Verwendung als Elektrolumineszenzmaterialien |
| US5650408A (en) | 1995-06-07 | 1997-07-22 | Karanewsky; Donald S. | Thiazolo benzazepine containing dual action inhibitors |
| TW434240B (en) | 1995-06-20 | 2001-05-16 | Zeneca Ltd | Aromatic compounds, preparation thereof and pharmaceutical composition comprising same |
| JP3895404B2 (ja) | 1996-05-17 | 2007-03-22 | 興和株式会社 | カルコン誘導体及びこれを含有する医薬 |
| WO1997041120A1 (en) | 1996-07-26 | 1997-11-06 | Dr. Reddy's Research Foundation | Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof |
| US6630496B1 (en) | 1996-08-26 | 2003-10-07 | Genetics Institute Llc | Inhibitors of phospholipase enzymes |
| CA2264020A1 (en) | 1996-08-26 | 1998-03-05 | Jean Bemis | Inhibitors of phospholipase enzymes |
| WO1998009967A1 (fr) * | 1996-09-09 | 1998-03-12 | Kyowa Hakko Kogyo Co., Ltd. | Derives de pyrrolocarbazole |
| BR9713027A (pt) | 1996-11-12 | 2000-01-25 | Novartis Ag | Derivados de pirazol úteis como herbicidas |
| US6043389A (en) | 1997-03-11 | 2000-03-28 | Mor Research Applications, Ltd. | Hydroxy and ether-containing oxyalkylene esters and uses thereof |
| FR2761687B1 (fr) | 1997-04-08 | 2000-09-15 | Centre Nat Rech Scient | Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques |
| US5760232A (en) | 1997-06-16 | 1998-06-02 | Schering Corporation | Synthesis of intermediates useful in preparing bromo-substituted tricyclic compounds |
| US6214817B1 (en) | 1997-06-20 | 2001-04-10 | Monsanto Company | Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity |
| US6011042A (en) | 1997-10-10 | 2000-01-04 | Enzon, Inc. | Acyl polymeric derivatives of aromatic hydroxyl-containing compounds |
| US6111107A (en) | 1997-11-20 | 2000-08-29 | Enzon, Inc. | High yield method for stereoselective acylation of tertiary alcohols |
| HUP0301166A2 (en) | 1997-12-12 | 2003-08-28 | Euro Celtique Sa | 3-substituted adenines via2-thioxanthines |
| KR20010041346A (ko) | 1998-02-25 | 2001-05-15 | 브루스 엠. 에이센, 토마스 제이 데스로저 | 포스포리파제 ａ2 억제제 |
| JP2002506873A (ja) | 1998-03-18 | 2002-03-05 | アリアド・ファーマシューティカルズ・インコーポレイテッド | 複素環式シグナル伝達阻害剤、それを含む組成物 |
| US6214879B1 (en) | 1998-03-24 | 2001-04-10 | Virginia Commonwealth University | Allosteric inhibitors of pyruvate kinase |
| US6153655A (en) | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
| GB9810860D0 (en) | 1998-05-20 | 1998-07-22 | Hoechst Schering Agrevo Gmbh | Substituted pyridine and pyrimidines, processes for their preparation and their use as pesticides |
| US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| IL139811A0 (en) | 1998-06-04 | 2002-02-10 | Abbott Lab | Cell adhesion-inhibiting antinflammatory compounds |
| GB9818627D0 (en) | 1998-08-26 | 1998-10-21 | Glaxo Group Ltd | Improvements in dva vaccination |
| GB9823871D0 (en) | 1998-10-30 | 1998-12-23 | Pharmacia & Upjohn Spa | 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents |
| US20030060425A1 (en) | 1998-11-24 | 2003-03-27 | Ahlem Clarence N. | Immune modulation method using steroid compounds |
| HRP20010427A2 (en) | 1998-12-14 | 2002-06-30 | Hoffmann La Roche | Phenylglycine derivatives |
| EP1150957A1 (en) | 1998-12-31 | 2001-11-07 | Aventis Pharmaceuticals Inc. | N-carboxymethyl substituted benzolactams as inhibitors of matrix metalloproteinase |
| US6544980B2 (en) | 1998-12-31 | 2003-04-08 | Aventis Pharmaceuticals Inc. | N-carboxymethyl substituted benzolactams as inhibitors of matrix metalloproteinase |
| JP2002541134A (ja) | 1999-03-31 | 2002-12-03 | ビーエーエスエフ アクチェンゲゼルシャフト | 置換アニリン化合物 |
| US6251927B1 (en) | 1999-04-20 | 2001-06-26 | Medinox, Inc. | Methods for treatment of sickle cell anemia |
| WO2000069472A2 (en) | 1999-05-14 | 2000-11-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Enzyme-activated anti-tumor prodrug compounds |
| US6184228B1 (en) | 1999-05-25 | 2001-02-06 | Anadys Pharmaceuticals, Inc. | Anti-sickling agents: selection methods and effective compounds |
| HK1045306A1 (zh) | 1999-06-03 | 2002-11-22 | Abbott Laboratories | 抑制细胞黏附的抗炎化合物 |
| AUPQ105499A0 (en) | 1999-06-18 | 1999-07-08 | Biota Scientific Management Pty Ltd | Antiviral agents |
| EA005027B1 (ru) | 1999-06-28 | 2004-10-28 | Янссен Фармацевтика Н.В. | Ингибиторы репликации респираторно-синцитиального вируса |
| US6599917B1 (en) | 1999-09-28 | 2003-07-29 | Eisai Co., Ltd. | Quinuclidine compounds and drugs containing the same as the active ingredient |
| AU2622301A (en) | 1999-11-05 | 2001-05-14 | Emisphere Technologies, Inc. | Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
| AUPQ407699A0 (en) | 1999-11-16 | 1999-12-09 | Fujisawa Pharmaceutical Co., Ltd. | Aminoalcohol derivatives |
| AU2001230537A1 (en) | 2000-02-01 | 2001-08-14 | Daiichi Pharmaceutical Co., Ltd. | Pyridoxazine derivatives |
| US6506755B2 (en) | 2000-02-03 | 2003-01-14 | Hoffmann-La Roche Inc. | Thiazolidinecarboxyl acids |
| AUPQ585000A0 (en) | 2000-02-28 | 2000-03-16 | Fujisawa Pharmaceutical Co., Ltd. | Aminoalcohol derivatives |
| WO2001070663A2 (en) | 2000-03-17 | 2001-09-27 | Corixa Corporation | Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors |
| AUPQ841300A0 (en) | 2000-06-27 | 2000-07-20 | Fujisawa Pharmaceutical Co., Ltd. | New aminoalcohol derivatives |
| CA2415890C (en) | 2000-07-14 | 2009-04-07 | F. Hoffmann-La Roche Ag | N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives |
| AU2001281071A1 (en) | 2000-08-01 | 2002-02-13 | Gmp Companies, Inc. | Ammonium salts of hemoglobin allosteric effectors, and uses thereof |
| US6653313B2 (en) | 2000-08-10 | 2003-11-25 | Warner-Lambert Company Llc | 1,4-dihydropyridine compounds as bradykinin antagonists |
| JP4272338B2 (ja) | 2000-09-22 | 2009-06-03 | バイエル アクチェンゲゼルシャフト | ピリジン誘導体 |
| AUPR034000A0 (en) | 2000-09-25 | 2000-10-19 | Fujisawa Pharmaceutical Co., Ltd. | Aminoalcohol derivatives |
| WO2002051849A1 (en) | 2000-12-26 | 2002-07-04 | Daiichi Pharmaceutical Co., Ltd. | Cdk4 inhibitors |
| ATE433964T1 (de) | 2000-12-28 | 2009-07-15 | Takeda Pharmaceutical | Alkansäurederivate, verfahren zu deren herstellung und deren verwendung |
| GB0102595D0 (en) | 2001-02-01 | 2001-03-21 | Virk Kuldip | Smart solar |
| US20030022923A1 (en) | 2001-03-01 | 2003-01-30 | Medinox, Inc. | Methods for treatment of sickle cell anemia |
| US6627646B2 (en) | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
| EP1435894A4 (en) | 2001-07-23 | 2005-07-06 | Galileo Pharmaceuticals Inc | CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS AND METHOD |
| JP2003075970A (ja) | 2001-08-31 | 2003-03-12 | Konica Corp | ハロゲン化銀カラー写真感光材料、カラー写真感光材料、その画像形成方法及びデジタル画像情報作製方法 |
| KR100467313B1 (ko) | 2001-11-22 | 2005-01-24 | 한국전자통신연구원 | 적색 유기 전기발광 화합물 및 그 제조 방법과 전기발광소자 |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| MXPA04005864A (es) | 2001-12-19 | 2004-10-29 | Atherogenics Inc | Derivados de charcona y su uso para tratar enfermedades. |
| US20030190333A1 (en) | 2002-02-04 | 2003-10-09 | Corixa Corporation | Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins |
| EP1542704A1 (en) | 2002-04-18 | 2005-06-22 | Stephen H. Embury | Method and composition for preventing pain in sickle cell patients |
| US6608076B1 (en) | 2002-05-16 | 2003-08-19 | Enzon, Inc. | Camptothecin derivatives and polymeric conjugates thereof |
| GB0212785D0 (en) | 2002-05-31 | 2002-07-10 | Glaxo Group Ltd | Compounds |
| BR0313160A (pt) | 2002-08-08 | 2005-07-12 | Smithkline Beecham Corp | Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto |
| AU2003257666A1 (en) | 2002-08-23 | 2004-03-11 | Kirin Beer Kabushiki Kaisha | COMPOUND HAVING TGFss INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME |
| WO2004024705A1 (ja) | 2002-09-10 | 2004-03-25 | Takeda Pharmaceutical Company Limited | ５員複素環化合物 |
| AU2003296022B2 (en) | 2002-12-04 | 2007-01-25 | Virginia Commonwealth University | Anti-sickling agents |
| AU2003303239A1 (en) | 2002-12-19 | 2004-07-14 | Atherogenics, Inc. | Process of making chalcone derivatives |
| WO2004058790A1 (ja) | 2002-12-25 | 2004-07-15 | Kissei Pharmaceutical Co., Ltd. | 含窒素複素環誘導体、それを含有する医薬組成物およびその医薬用途 |
| WO2004073675A1 (de) | 2003-02-24 | 2004-09-02 | Randolph Riemschneider | Kosmetische zusammensetzung mit whitening-effekt, verfahren zu ihrer herstellung und ihre verwendung |
| US20040186077A1 (en) | 2003-03-17 | 2004-09-23 | Medicure International Inc. | Novel heteroaryl phosphonates as cardioprotective agents |
| ZA200507752B (en) | 2003-03-28 | 2007-01-31 | Threshold Pharmaceuticals Inc | Compositions and methods for treating cancer |
| EP1613613B1 (en) | 2003-04-11 | 2021-06-02 | Genzyme Corporation | Cxcr4 chemokine receptor binding compounds |
| RU2337908C2 (ru) | 2003-06-12 | 2008-11-10 | Ново Нордиск А/С | Пиридинилкарбаматы в качестве ингибиторов гормон-чувствительной липазы |
| WO2005019220A2 (en) | 2003-08-11 | 2005-03-03 | Cellular Genomics Inc. | Substituted imidazo[1,2-a]pyrazines as modulators of kinase activity |
| US7411083B2 (en) | 2003-09-25 | 2008-08-12 | Wyeth | Substituted acetic acid derivatives |
| BRPI0416283A (pt) | 2003-11-05 | 2007-01-23 | Hoffmann La Roche | compostos, processo para a fabricação de compostos, composição farmacêutica, método para o tratamento e/ou prevenção de doenças que são moduladas por agonistas de ppar(delta) e/ou ppar(alfa) e uso destes compostos |
| AU2004289690A1 (en) | 2003-11-10 | 2005-05-26 | Schering Aktiengesellschaft | Benzylether amine compounds useful as CCR-5 antagonists |
| EP1694328A4 (en) | 2003-12-02 | 2010-02-17 | Celgene Corp | METHOD AND COMPOSITIONS FOR THE TREATMENT AND SUPPLY OF HEMOGLOBINOPATHY AND ANEMIA |
| US7378439B2 (en) | 2004-01-20 | 2008-05-27 | Usv, Ltd. | Process for the preparation of 4-(2-dipropylaminoethyl)-1,3-dihydro-2H-indol-2-one hydrochloride |
| AU2005211349A1 (en) | 2004-01-30 | 2005-08-18 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | N-benzyl-3,4-dihyroxypyridine-2-carboxamide and N-benzyl-2,3-dihydroxypyridine-4-carboxamide compounds useful as HIV integrase inhibitors |
| GB0403038D0 (en) | 2004-02-11 | 2004-03-17 | Novartis Ag | Organic compounds |
| WO2005087766A1 (en) | 2004-03-09 | 2005-09-22 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Hiv integrase inhibitors |
| WO2005086951A2 (en) | 2004-03-10 | 2005-09-22 | Threshold Pharmaceuticals, Inc. | Hypoxia-activated anti-cancer agents |
| DE102004015226B3 (de) | 2004-03-24 | 2005-08-25 | Siemens Ag | Verfahren zum Plasmareinigen eines Werkstücks und zu dessen Durchführung geeignete Vorrichtung |
| JP2007534691A (ja) | 2004-04-22 | 2007-11-29 | アロス・セラピューティクス・インコーポレーテッド | アロステリックヘモグロビン修飾体の組成物および前記組成物の製造法 |
| TW200606133A (en) | 2004-06-30 | 2006-02-16 | Sankyo Co | Substituted benzene compounds |
| TW200606129A (en) | 2004-07-26 | 2006-02-16 | Chugai Pharmaceutical Co Ltd | Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same |
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| CA2585165A1 (en) | 2004-10-28 | 2006-05-18 | Medicure International Inc. | Dual antiplatelet/anticoagulant pyridoxine analogs |
| EP1831170A4 (en) | 2004-12-14 | 2009-10-14 | Astrazeneca Ab | SUBSTITUTED AMINOPYRIDINES AND THEIR USE |
| ATE516026T1 (de) | 2005-02-21 | 2011-07-15 | Shionogi & Co | Bicyclisches carbamoylpyridonderivat mit hiv- integrase-hemmender wirkung |
| WO2006106711A1 (ja) | 2005-03-30 | 2006-10-12 | Eisai R & D Management Co., Ltd. | ピリジン誘導体を含有する抗真菌剤 |
| GB0506677D0 (en) | 2005-04-01 | 2005-05-11 | Btg Int Ltd | Iron modulators |
| DK1874117T3 (da) | 2005-04-28 | 2013-09-23 | Viiv Healthcare Co | Polycyklisk carbamoylpyridonderivat med hiv-integrasehæmmende aktivitet |
| DE102005025989A1 (de) | 2005-06-07 | 2007-01-11 | Bayer Cropscience Ag | Carboxamide |
| JP2006342115A (ja) | 2005-06-10 | 2006-12-21 | Shionogi & Co Ltd | Ｈｉｖインテグラーゼ阻害活性を有する多環性化合物 |
| EP2308840A1 (en) | 2005-06-30 | 2011-04-13 | Prosidion Limited | GPCR agonists |
| CN100562514C (zh) | 2005-07-22 | 2009-11-25 | 中国科学院上海药物研究所 | 一类取代丙酰胺衍生物、其制备方法和用途 |
| GB0516270D0 (en) | 2005-08-08 | 2005-09-14 | Glaxo Group Ltd | Novel compounds |
| SI1945622T1 (sl) | 2005-10-11 | 2012-05-31 | Univ Pittsburgh | Izotopično markirane spojine benzfurana kot označevalne snovi za amiloidogenske proteine |
| JP5131689B2 (ja) | 2005-10-27 | 2013-01-30 | 塩野義製薬株式会社 | Ｈｉｖインテグラーゼ阻害活性を有する多環性カルバモイルピリドン誘導体 |
| WO2007061923A2 (en) | 2005-11-18 | 2007-05-31 | Takeda San Diego, Inc. | Glucokinase activators |
| WO2007084914A2 (en) | 2006-01-17 | 2007-07-26 | Neurocrine Biosciences, Inc. | Phenoxy-substituted pyrimidines as adenosine receptor antagonists |
| RU2318818C1 (ru) | 2006-04-12 | 2008-03-10 | Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" | Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты) |
| GB0614586D0 (en) | 2006-07-22 | 2006-08-30 | Pliva Istrazivacki Inst D O O | Pharmaceutical Formulation |
| CN101113148A (zh) | 2006-07-26 | 2008-01-30 | 中国海洋大学 | 二氧哌嗪类化合物及其制备方法和用途 |
| CA2658925C (en) | 2006-07-27 | 2015-07-14 | Amorepacific Corporation | Novel sulfonylamino acrylamide derivatives, isomer thereof,or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same |
| TW200817424A (en) | 2006-08-04 | 2008-04-16 | Daiichi Sankyo Co Ltd | Benzylphenyl glucopyranoside derivatives |
| TWI389895B (zh) | 2006-08-21 | 2013-03-21 | Infinity Discovery Inc | 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法 |
| CA2661649C (en) | 2006-09-03 | 2014-12-30 | Techfields Biochem Co. Ltd | Positively charged water-soluble prodrugs of acetaminophen and related compounds with very fast skin penetration rate |
| JP2010505811A (ja) | 2006-10-04 | 2010-02-25 | ファイザー・プロダクツ・インク | カルシウム受容体アンタゴニストとしてのピリド［４，３−ｄ］ピリミジン−４（３Ｈ）−オン誘導体 |
| MX2009004385A (es) | 2006-10-23 | 2009-05-22 | Merck & Co Inc | Derivados de 2-[1-fenil-5-hidroxi-4alfa-metil-hexahidrociclopenta [f]indazol-5-il]etil fenilo como ligandos del receptor glucocorticoide. |
| TW200835687A (en) | 2006-11-30 | 2008-09-01 | R Tech Ueno Ltd | Thiazole derivatives and their use as VAP-1 inhibitor |
| JP2008137914A (ja) | 2006-11-30 | 2008-06-19 | Rikogaku Shinkokai | β−セクレターゼ阻害剤 |
| EP2123637A4 (en) | 2006-11-30 | 2011-12-21 | Tokyo Inst Tech | NEW CURCUMIN DERIVATIVES |
| FR2909379B1 (fr) | 2006-11-30 | 2009-01-16 | Servier Lab | Nouveaux derives heterocycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| WO2008101682A2 (en) | 2007-02-22 | 2008-08-28 | Syngenta Participations Ag | Iminipyridine derivatives and their uses as microbiocides |
| TWI407960B (zh) | 2007-03-23 | 2013-09-11 | Jerini Ag | 小分子緩激肽ｂ２受體調節劑 |
| CN101679172B (zh) | 2007-05-22 | 2013-05-29 | 住友化学株式会社 | 苯甲醛化合物的制造方法 |
| WO2009001214A2 (en) | 2007-06-28 | 2008-12-31 | Pfizer Products Inc. | Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists |
| WO2009011850A2 (en) | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Novel therapeutic compounds |
| KR101158191B1 (ko) | 2007-07-17 | 2012-06-19 | 에프. 호프만-라 로슈 아게 | 11ｂ-하이드록시스테로이드 탈수소효소의 억제제 |
| ATE522249T1 (de) | 2007-07-26 | 2011-09-15 | Novartis Ag | Organische verbindungen |
| TW200918521A (en) | 2007-08-31 | 2009-05-01 | Astrazeneca Ab | Heterocyclic amides and methods of use thereof |
| JP5456681B2 (ja) | 2007-10-17 | 2014-04-02 | ノバルティス アーゲー | ＡＬＫ阻害剤として有用なイミダゾ［１，２−ａ］ピリジン誘導体 |
| JP5301557B2 (ja) | 2007-12-04 | 2013-09-25 | エフ．ホフマン−ラ ロシュ アーゲー | イソオキサゾロ−ピリジン誘導体 |
| US7776875B2 (en) | 2007-12-19 | 2010-08-17 | Hoffman-La Roche Inc. | Spiroindolinone derivatives |
| JP2009203230A (ja) | 2008-01-31 | 2009-09-10 | Daiichi Sankyo Co Ltd | ベンジルフェニルグルコピラノシド誘導体を含有する医薬組成物 |
| US8258349B2 (en) * | 2008-02-14 | 2012-09-04 | Suitomo Chemical Company, Limited | Process for production of benzaldehyde compound |
| BRPI0906348A2 (pt) | 2008-04-11 | 2019-07-16 | Inst Of Medicinal Molecular Designer Inc | composto representado pela fórmula (1), composição farmacêutica; inibidor pai-1 e medicamento para prevenção para prevenção e/ou tratamento terapêutico de doença causada pela manifestação de pai-1 ou pelo aumento da ação de pai-1 |
| US8633245B2 (en) | 2008-04-11 | 2014-01-21 | Institute Of Medicinal Molecular Design, Inc. | PAI-1 inhibitor |
| JP2011136906A (ja) | 2008-04-18 | 2011-07-14 | Otsuka Pharmaceut Co Ltd | 複素環化合物 |
| US8119647B2 (en) | 2008-04-23 | 2012-02-21 | Glenmark Pharmaceuticals S.A. | Fused pyrimidineone compounds as TRPV3 modulators |
| CA2723233C (en) | 2008-05-08 | 2017-06-13 | Nova Southeastern University | Specific inhibitors for vascular endothelial growth factor receptors |
| WO2009146555A1 (en) | 2008-06-04 | 2009-12-10 | Ambrilia Biopharma Inc. | Hiv integrase inhibitors from pyridoxine |
| DE102008027574A1 (de) | 2008-06-10 | 2009-12-17 | Merck Patent Gmbh | Neue Pyrrolidinderivate als MetAP-2 Inhibitoren |
| JP5314330B2 (ja) | 2008-06-16 | 2013-10-16 | 住友化学株式会社 | ２−（アリールオキシメチル）ベンズアルデヒドの製造方法およびその中間体 |
| GB0811451D0 (en) | 2008-06-20 | 2008-07-30 | Syngenta Participations Ag | Novel microbiocides |
| AR073304A1 (es) | 2008-09-22 | 2010-10-28 | Jerini Ag | Moduladores del receptor de bradiquinina b2 de molecula pequena |
| JP2012508692A (ja) | 2008-11-12 | 2012-04-12 | シェーリング コーポレイション | 脂肪酸結合タンパク質（ｆａｂｐ）の阻害薬 |
| JP2010168314A (ja) * | 2009-01-23 | 2010-08-05 | Daiichi Sankyo Co Ltd | ベンゼン化合物の製造のための中間体およびその製造方法 |
| TW201033201A (en) | 2009-02-19 | 2010-09-16 | Hoffmann La Roche | Isoxazole-isoxazole and isoxazole-isothiazole derivatives |
| HUE049450T2 (hu) | 2009-03-31 | 2020-09-28 | Ligand Pharm Inc | Endotelin és angiotenzin II receptor antagonista bifenilszulfonamid glomeruloszklerózis és IgA által kiváltott nefropátia kezelésére |
| ES2440000T3 (es) | 2009-05-08 | 2014-01-27 | Tetraphase Pharmaceuticals, Inc. | Compuestos de 8-aza-tetraciclina |
| EP2471789B9 (en) | 2009-08-26 | 2015-03-25 | Takeda Pharmaceutical Company Limited | Fused heterocyclic ring derivative and use thereof |
| EP2474540A4 (en) | 2009-08-31 | 2013-03-13 | Nippon Chemiphar Co | GPR119 AGONIST |
| BR112012005616A2 (pt) | 2009-09-21 | 2016-06-21 | Hoffmann La Roche | compostos antivirais heterocíclicos |
| NZ599763A (en) | 2009-11-09 | 2014-06-27 | Wyeth Llc | Tablet formulations of neratinib maleate |
| TW201139406A (en) | 2010-01-14 | 2011-11-16 | Glaxo Group Ltd | Voltage-gated sodium channel blockers |
| KR101698153B1 (ko) | 2010-04-26 | 2017-01-23 | 광주과학기술원 | Ｐ2ｘ1 및 ｐ2ｘ3 수용체 길항제로 사용되는 신규한 피리딘 카르복실산계 화합물, 이의 제조방법 및 이를 포함하는 조성물 |
| CN102232949A (zh) | 2010-04-27 | 2011-11-09 | 孙远 | 提高药物溶出度的组合物及其制备方法 |
| TWI535442B (zh) | 2010-05-10 | 2016-06-01 | Kyowa Hakko Kirin Co Ltd | A nitrogen-containing heterocyclic compound having an action of inhibiting the production of canine erythritine |
| US20120122928A1 (en) | 2010-08-11 | 2012-05-17 | Bayer Cropscience Ag | Heteroarylpiperidine and -Piperazine Derivatives as Fungicides |
| CN102116772B (zh) | 2010-09-28 | 2013-08-28 | 上海大学 | 二氢查尔酮化合物的筛选方法 |
| JP2014501224A (ja) | 2010-12-27 | 2014-01-20 | 武田薬品工業株式会社 | 口腔内崩壊錠 |
| BR112013025680A2 (pt) | 2011-04-06 | 2017-01-03 | Teva Pharma | Novos intermediários e processos para preparar ticagrelor |
| CN103717588B (zh) | 2011-04-11 | 2016-08-03 | 绿色科技株式会社 | 吡唑衍生物 |
| PE20142353A1 (es) | 2011-09-15 | 2015-01-10 | Demerx Inc | Ansolvatos de sal de noribogaina |
| US20140308260A1 (en) | 2011-10-07 | 2014-10-16 | Radiorx, Inc. | Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products |
| ES2790358T3 (es) | 2011-12-28 | 2020-10-27 | Global Blood Therapeutics Inc | Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular |
| JP5906489B2 (ja) * | 2012-05-18 | 2016-04-20 | 新日鉄住金化学株式会社 | ポルフィリン色素並びにポルフィリン色素を用いた色素増感太陽電池及び光電変換素子 |
| BR112015015216B1 (pt) | 2012-12-27 | 2020-01-07 | Sumitomo Chemical Company, Limited | Composto de tetrazolinona, agente e método de controle de peste |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| EA201591427A1 (ru) | 2013-03-15 | 2016-01-29 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| US20150057251A1 (en) | 2013-08-26 | 2015-02-26 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US20140271591A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compositions and methods for the modulation of hemoglobin (s) |
| US20140274961A1 (en) * | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| EP2968299B1 (en) | 2013-03-15 | 2021-01-20 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
| CA2902709A1 (en) | 2013-03-15 | 2014-09-25 | Global Blood Therapeutics, Inc. | Compositions and methods for the modulation of hemoglobin (s) |
| EP3919056B1 (en) | 2013-03-15 | 2024-08-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| CN112500338A (zh) | 2013-03-15 | 2021-03-16 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
| ES2710380T3 (es) | 2013-03-15 | 2019-04-24 | Global Blood Therapeutics Inc | Compuestos y usos de los mismos para la modulación de hemoglobina |
| US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
| US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US20160206604A1 (en) | 2013-08-26 | 2016-07-21 | Global Blood Therapeutics, Inc. | Formulations comprising wetting agents and compounds for the modulation of hemoglobin (s) |
| WO2015031285A1 (en) | 2013-08-27 | 2015-03-05 | Global Blood Therapeutics, Inc. | Crystalline 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde ansolvate salts |
| US20160207904A1 (en) | 2013-08-27 | 2016-07-21 | Global Blood Therapeutics, Inc. | Crystalline 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde ansolvate salts |
| US20150141465A1 (en) | 2013-11-18 | 2015-05-21 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| WO2015116061A1 (en) * | 2014-01-29 | 2015-08-06 | Global Blood Therapeutics, Inc. | 1:1 adducts of sickle hemoglobin |
| US9248199B2 (en) | 2014-01-29 | 2016-02-02 | Global Blood Therapeutics, Inc. | 1:1 adducts of sickle hemoglobin |
| MA41841A (fr) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs |
| HUE072191T2 (hu) | 2015-12-04 | 2025-10-28 | Global Blood Therapeutics Inc | A 2-hidoxi-6-((2-(1-izopropil-1H-pirazol-5-il)piridin-3-il)metoxi)benzaldehid adagolási rendje |
| TWI825524B (zh) | 2016-05-12 | 2023-12-11 | 美商全球血液治療公司 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
| TWI778983B (zh) | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
-
2017
- 2017-05-10 TW TW110146540A patent/TWI825524B/zh active
- 2017-05-10 TW TW108110285A patent/TWI752307B/zh active
- 2017-05-10 AR ARP170101226A patent/AR108435A1/es unknown
- 2017-05-10 TW TW106115528A patent/TWI663160B/zh active
- 2017-05-11 EA EA201892151A patent/EA037014B1/ru unknown
- 2017-05-11 CN CN202211452933.5A patent/CN115819400A/zh active Pending
- 2017-05-11 EA EA202092636A patent/EA202092636A1/ru unknown
- 2017-05-11 HR HRP20211193TT patent/HRP20211193T1/hr unknown
- 2017-05-11 EP EP21168857.7A patent/EP3909941A1/en active Pending
- 2017-05-11 US US15/593,198 patent/US10077249B2/en active Active
- 2017-05-11 KR KR1020227034189A patent/KR20220139437A/ko not_active Withdrawn
- 2017-05-11 PL PL17796828T patent/PL3454854T3/pl unknown
- 2017-05-11 AU AU2017261730A patent/AU2017261730B2/en not_active Ceased
- 2017-05-11 KR KR1020237033799A patent/KR20230146119A/ko not_active Ceased
- 2017-05-11 WO PCT/US2017/032104 patent/WO2017197083A1/en not_active Ceased
- 2017-05-11 JP JP2018558768A patent/JP7398193B2/ja active Active
- 2017-05-11 SG SG11201809344QA patent/SG11201809344QA/en unknown
- 2017-05-11 IL IL284406A patent/IL284406B2/en unknown
- 2017-05-11 SG SG10201912288VA patent/SG10201912288VA/en unknown
- 2017-05-11 DK DK17796828.6T patent/DK3454854T3/da active
- 2017-05-11 IL IL297055A patent/IL297055B2/en unknown
- 2017-05-11 MX MX2020013114A patent/MX387149B/es unknown
- 2017-05-11 EP EP17796828.6A patent/EP3454854B1/en active Active
- 2017-05-11 HU HUE17796828A patent/HUE055045T2/hu unknown
- 2017-05-11 PT PT177968286T patent/PT3454854T/pt unknown
- 2017-05-11 ES ES17796828T patent/ES2881426T3/es active Active
- 2017-05-11 CN CN201780028862.7A patent/CN109152770A/zh active Pending
- 2017-05-11 MX MX2018013099A patent/MX377901B/es unknown
- 2017-05-11 KR KR1020187035085A patent/KR102487509B1/ko active Active
-
2018
- 2018-08-10 US US16/101,251 patent/US10577345B2/en active Active
- 2018-10-25 MX MX2021012669A patent/MX2021012669A/es unknown
- 2018-11-05 IL IL262791A patent/IL262791B/en unknown
-
2021
- 2021-02-09 AU AU2021200802A patent/AU2021200802B2/en not_active Ceased
- 2021-06-03 US US17/337,895 patent/US20210284623A1/en not_active Abandoned
-
2022
- 2022-01-10 US US17/571,762 patent/US20220135533A1/en not_active Abandoned
- 2022-03-30 JP JP2022056031A patent/JP2022088564A/ja active Pending
- 2022-08-25 US US17/895,619 patent/US20230219922A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104135859A (zh) * | 2011-12-28 | 2014-11-05 | 全球血液疗法公司 | 取代的苯甲醛化合物及其用于增加组织氧合的方法 |
| TW201612171A (en) * | 2014-02-07 | 2016-04-01 | Global Blood Therapeutics Inc | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI825524B (zh) | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 | |
| JP2022533405A (ja) | カンナビジオール系化合物の製造方法 | |
| RU2552350C2 (ru) | Способ получения соединений бифенилимидазола | |
| HK40064525A (en) | Intermediates of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| CA3023662C (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| HK40005952B (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| HK40005952A (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| NZ788034A (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| CN113816955B (zh) | 一种ret激酶抑制剂中间体及其制备方法 | |
| BR112018072351B1 (pt) | Processo para a síntese de 2-hidróxi-6-((2-(1-isopropil1h-pirazol-5-il)-piridin-3- il)metóxi)benzaldeído | |
| JP6780958B2 (ja) | 結晶構造を有する１−（３−カルボキシピリジル−２−）−２−フェニル−４−メチルピペラジン及びその製造方法 |